Clinical Trial Update: Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated immunization with a gp100 protein vaccine in patients with metastatic melanoma and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• gp100 protein vaccine (gp100 peptide vaccine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED